You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 綠葉製藥(2186.HK)高開5.03% 新冠中和抗體已在中國完成I期臨牀試驗
格隆匯 05-06 09:26
格隆匯5月6日丨綠葉製藥(2186.HK)高開5.03%,報4.8港元,最新總市值169.99億港元。綠葉製藥今日早間發公吿稱,集團附屬公司山東博安生物技術股份有限公司所開發的治療新型冠狀病毒肺炎(“COVID-19”)的在研新藥LY-Cov Mab已在中國完成I期臨牀試驗。此次在中國完成的臨牀研究是一項評價LY-Cov Mab注射液單次給藥的安全性、耐受性、藥代動力學特徵及免疫原性的I期臨牀研究,共納入42例中國健康受試者。結果顯示,LY-Cov Mab具有良好的安全性和耐受性,為後期臨牀試驗提供了明確的參考依據。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account